Production (Stage)
BioMarin Pharmaceutical Inc.
BMRN
$57.55
-$0.46-0.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -0.29% | 0.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.29% | 0.21% | |||
| Cost of Revenue | 127.92% | -27.76% | |||
| Gross Profit | -28.85% | 9.67% | |||
| SG&A Expenses | 20.69% | -32.63% | |||
| Depreciation & Amortization | -49.78% | 92.67% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.36% | -22.44% | |||
| Operating Income | -12.96% | 125.86% | |||
| Income Before Tax | 40.35% | 26.18% | |||
| Income Tax Expenses | 17.24% | 57.60% | |||
| Earnings from Continuing Operations | 48.62% | 17.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.62% | 17.78% | |||
| EBIT | -12.96% | 125.86% | |||
| EBITDA | -12.42% | 111.32% | |||
| EPS Basic | 48.40% | 17.61% | |||
| Normalized Basic EPS | -10.45% | 97.21% | |||
| EPS Diluted | 47.99% | 17.81% | |||
| Normalized Diluted EPS | -10.26% | 98.03% | |||
| Average Basic Shares Outstanding | 0.15% | 0.14% | |||
| Average Diluted Shares Outstanding | -0.05% | -0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||